Last reviewed · How we verify
RO7126209
At a glance
| Generic name | RO7126209 |
|---|---|
| Also known as | Trontinemab, RG6102 |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease (PHASE1, PHASE2)
- A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (PHASE3)
- A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (PHASE3)
- A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO7126209 CI brief — competitive landscape report
- RO7126209 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI